



Supplementary Figure 1 Progression of metabolic deficits in DIO-NASH mice. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ (vs week 0).



Supplementary Figure 2 Histomorphological effects of liraglutide, obeticholic acid (OCA), and elafibranor treatment in DIO-NASH mice. Individual steatosis, inflammation and ballooning scores. * $P < 0.05$, *** $P < 0.001$ (*vs* vehicle controls).



Supplementary Figure 3 Histomorphological effects of liraglutide, obeticholic acid (OCA), and elafibranor in *ob/ob*-NASH mice. Individual steatosis, inflammation and ballooning scores. * $P < 0.05$, *** $P < 0.001$ (*vs* vehicle controls).